Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2014 1
2015 1
2016 1
2019 1
2020 3
2021 7
2022 3
2023 9
2024 12
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP. Müller C, et al. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27. Eur J Nucl Med Mol Imaging. 2019. PMID: 31134301 Free PMC article.
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177.
Trejtnar F, Bárta P, Kozempel J, Vlk M, Ďurinová A, Kuchařová M, Pávek P. Trejtnar F, et al. Nucl Med Biol. 2025 May-Jun;144-145:108998. doi: 10.1016/j.nucmedbio.2025.108998. Epub 2025 Feb 12. Nucl Med Biol. 2025. PMID: 39978166 Review.
Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nuclear medicine. Similarly to lutetium-177, the terbium-161 emits beta particles and gamma-radiation, although terbium- …
Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nu …
Alpha and Beta Radiation for Theragnostics.
Song H, Sgouros G. Song H, et al. PET Clin. 2024 Jul;19(3):307-323. doi: 10.1016/j.cpet.2024.03.006. Epub 2024 Apr 29. PET Clin. 2024. PMID: 38688775 Review.
Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.
Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Borgna F, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34625828 Free PMC article.
PURPOSE: The beta()-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DO …
PURPOSE: The beta()-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in kill …
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Alati S, et al. Semin Nucl Med. 2023 Sep;53(5):663-686. doi: 10.1053/j.semnuclmed.2023.06.007. Epub 2023 Jul 18. Semin Nucl Med. 2023. PMID: 37468417 Review.
While lutetium-177 ((177)Lu) remains the most widely used radionuclide, radiolabeled analogs with iodine-131 ((128)I), yttrium-90 ((89)Y), copper-67 ((67)Cu), and terbium-161 ((161)Tb) have been evaluated as potential alternatives in recent years. In addition, agent …
While lutetium-177 ((177)Lu) remains the most widely used radionuclide, radiolabeled analogs with iodine-131 ((128)I), yttrium-90 ((89)Y), c …
161Terbium-Labeled Gold Nanoparticles as Nanoscale Brachytherapy Agents Against Breast Cancer.
Salvanou EA, Apostolopoulou A, Xanthopoulos S, Koelewijn S, van Overeem P, Laurent G, Bazzi R, Denat F, Roux S, Bouziotis P. Salvanou EA, et al. Materials (Basel). 2025 Jan 8;18(2):248. doi: 10.3390/ma18020248. Materials (Basel). 2025. PMID: 39859720 Free PMC article.
Due to their intriguing emission profile, Terbium-161 ((161)Tb) radiopharmaceuticals seem to bring significant advancement in theranostic applications to cancer treatment. ...
Due to their intriguing emission profile, Terbium-161 ((161)Tb) radiopharmaceuticals seem to bring significant advancement in …
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Van Laere C, Koole M, Deroose CM, de Voorde MV, Baete K, Cocolios TE, Duchemin C, Ooms M, Cleeren F. Van Laere C, et al. Theranostics. 2024 Feb 17;14(4):1720-1743. doi: 10.7150/thno.92775. eCollection 2024. Theranostics. 2024. PMID: 38389843 Free PMC article. Review.
Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties enable the synthesis of radiopharmaceuticals with the same pharmacokinetic cha …
Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and …
Use of Terbium-161 [161Tb]Tb-DOTATATE in Recurrent Paraganglioma.
Jacobs N, Solomon T, Kolade O, Hlongwa K, More S. Jacobs N, et al. Clin Nucl Med. 2025 May 16. doi: 10.1097/RLU.0000000000005897. Online ahead of print. Clin Nucl Med. 2025. PMID: 40392129
This report explores the application of terbium-161 [(161Tb)Tb] DOTATATE in the case of a 31-year-old man with recurrent paraganglioma. ...
This report explores the application of terbium-161 [(161Tb)Tb] DOTATATE in the case of a 31-year-old man with recurrent parag …
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting.
Busslinger SD, Mapanao AK, Kegler K, Bernhardt P, Flühmann F, Fricke J, Zeevaart JR, Köster U, van der Meulen NP, Schibli R, Müller C. Busslinger SD, et al. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4049-4061. doi: 10.1007/s00259-024-06827-2. Epub 2024 Jul 24. Eur J Nucl Med Mol Imaging. 2024. PMID: 39046521 Free PMC article.
Impressive preclinical data obtained with [(161)Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of (161)Tb- and (177)Lu-based DOTA-LM3 and DOT …
Impressive preclinical data obtained with [(161)Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as …
44 results